ARS Pharmaceuticals (SPRY) Long-Term Deferred Tax (2023 - 2025)

ARS Pharmaceuticals has reported Long-Term Deferred Tax for 3 years, with the latest figure at $73.4 million in Q4 2025.

• Quarterly Long-Term Deferred Tax rose 99.13% year-over-year to $73.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $73.4 million (up 99.13% YoY) and the FY2025 annual result came in at $73.4 million, up 99.13% from the prior year.
• Long-Term Deferred Tax climbed to $73.4 million in Q4 2025 per SPRY's latest filing, from $36.9 million in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $73.4 million in Q4 2025 and troughed at $29.0 million in Q4 2023.
• A 3-year average of $46.4 million and a median of $36.9 million in 2024 frame the typical range for Long-Term Deferred Tax.
• The sharpest annual moves came in 2024 and 2025: Long-Term Deferred Tax advanced 26.92% in 2024, then surged 99.13% in 2025.
• Over 3 years, Long-Term Deferred Tax stood at $29.0 million in 2023, then advanced by 26.92% to $36.9 million in 2024, then soared by 99.13% to $73.4 million in 2025.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $73.4 million, $36.9 million, and $29.0 million for Q4 2025, Q4 2024, and Q4 2023 respectively.